Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Inclusion Criteria: * A diagnosis of acute myeloid leukemia (AML) according to the World Health Organization 2008 criteria with relapsed or refractory disease and ineligible for or have exhausted standard therapeutic options * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 * Hematology laboratory parameters within the Protocol specified range * Chemistry laboratory parameters within the Protocol specified range * A woman of childbearing potential must have a negative highly sensitive serum (beta human chorionic gonadotropin \[b-hCG\]) or urine test prior to the first dose of study drug Exclusion Criteria: * Acute promyelocytic leukemia * Active central nervous system involvement * Prior solid organ transplantation * Prior hematopoietic stem cell transplant within 6 months of enrollment. If the participant had an allogenic transplant there must be no apparent signs of graft versus host disease and participants must have discontinued all immunosuppressive therapies for at least 4 weeks * Prior treatment with a CD123xCD3 bispecific agent, T cells expressing CD123 specific chimeric antigen receptor, or toxin-conjugated to CD123 antibodies; prior treatment with naked anti-CD123 monoclonal antibody is permitted